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Abstract. The p53 tumor suppressor protein has been 
implicated as a mediator of programmed cell death 
(PCD). A series of nontransformed mammary epithe- 
lial cell (MEC) lines were used to correlate p53 func- 
tion with activation of PCD. Treatment of MECs 
expressing mutant, inactive, or no p53 with DNA- 
damaging agents did not induce apoptosis. Upon 
introduction of temperature-sensitive p53into HC11 
cells, which lack wild-type (wt) p53, PCD was ob- 
served after mitomycin treatment at 32 °, when the ts 
p53 protein is in wt conformation. Thus, wt p53 
mediates activation of PCD in response to mitomycin 
in HCll cells. Treatment of the MCF10-A cells, which 
express wt p53, with various DNA-damaging agents 
led to nuclear accumulation of p53. Only mitomycin 
treatment led to an increase in the number of apop- 
totic nuclei. ErbB-2-transformed MCF10-A cells 
responded to mitomycin, cisplatin, and 5-Fl-uracil, 
suggesting that signaling from activated ErbB-2 en- 
hances the cells ability to respond to DNA damage. A 
combination of high cell density and serum-free 
medium induces apoptosis in all MECs tested, ir- 
respective of their p53 status. Under these conditions, 
EGF or insulin act as survival factors in preventing 
PCD. These data might elucidate some aspects of 
breast involution and tumorigenesis. 
T rIE p53 tumor suppressor p otein is a potent inhibitor 
of cell growth and transformation, and is involved in 
the cellular response to DNA damage (reviewed in 
Zambetti and Levine, 1993; Lane, 1992). After irradiation- 
or chemically induced DNA damage, wild-type (wt) ~ p53 
rapidly accumulates in the cell nucleus (Fritsche et al., 
1993; Hall et al., 1993), and it orchestrates a number of nu- 
clear events leading to a cell cycle arrest at the G1/S phase 
transition (Kastan et al., 1991; Kuerbitz et al., 1992). One 
of these events is the transcriptional ctivation of the p21/ 
waf-1/pic-1 cyclin inhibitory gene (E1-Deiry et al., 1993). 
During this cell cycle arrest, the cells would be allowed 
to repair the damaged DNA and then reenter the cell cy- 
cle (Lane, 1992). The DNA damage-induced cell cycle ar- 
rest requires wt p53 function (Kastan et al., 1991; Kuerbitz 
et al., 1992). A number of experiments have also indicated 
that wt p53 can mediate DNA damage-induced programmed 
cell death (PCD), presumably when the damage is excessive 
and incompatible with DNA replication (Barry et al., 1990; 
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Kastan et al., 1991; Kuerbitz et al., 1992; Lowe et al., 
1993a, b). Perhaps the most convincing evidence is that 
thymocytes from p53-deficient mice fail to undergo PCD af- 
ter irradiation (Clarke et al., 1993; Lowe et al., 1993b). 
The importance of understanding the involvement of the 
p53 tumor suppressor p otein in the activation of PCD lies 
in the high frequency of p53 mutations found in human can- 
cer (Hollstein et al., 1991), including breast cancer (Harris, 
1992; Osborne t al., 1991). Potent DNA-damaging agents 
are commonly used in cancer chemotherapy (Calabresi and 
Chabner, 1993), and tumor regression after chemotherapy 
is caused, at least in part, by the ability of DNA-damaging 
drugs to activate PCD of the neoplastic ells. Absence of wt 
p53 might abolish this response to DNA damage and result 
in drug resistance. Most of the data in the literature were ob- 
tained from thymocytes (Clarke et al., 1993), lymphoid, or 
fibroblast cells (Lowe et al., 1993a, b) and very little is 
known for mammary epithelial cells (MEC). Since breast 
carcinoma represents he most frequent neoplasia in women, 
it is relevant o examine the mechanisms of cell death in 
mammary cells. 
PCD is an active cellular process that is involved in a vari- 
ety of physiological events in which rapid elimination of un- 
wanted cells must occur. Its importance in the turnover of 
self-renewing tissues, morphogenesis, embryonic develop- 
ment, maturation of cells of the immune system (reviewed 
in: Kerr et al., 1972; Wyllie, 1992; Cohen et al., 1992; Raft, 
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1993), as well as in the development of cancer and other 
pathologies (reviewed in: Sen and D'Incalci, 1992; Barr and 
Tomei, 1994), is increasingly being recognized. During the 
differentiation cycle of the mammary gland, massive apopto- 
sis occurs at the cessation of lactation and leads to rapid in- 
volution of the gland to its puberal state (Walker et al., 1989; 
Strange t al., 1992). Features of cells undergoing PCD in- 
clude chromatin condensation and nuclear fragmentation, 
internucleosomal DNA cleavage, shrinking, and appearance 
of apoptotic bodies, the hallmarks of a process also known 
as apoptosis (Kerr et al., 1972; Wyllie, 1980, 1984). Apop- 
tosis is physiologically triggered by extracellular signals of 
a different nature, which appear to be cell type specific. The 
data indicate that both negative and positive apoptotic sig- 
nals exist which can, respectively, prevent or induce PCD. 
Certain cell types are dependent on and compete for ex- 
tracellular factors for their survival, which act by preventing 
the execution of PCD (Raft, 1993). Several examples have 
now been reported (Banes et al., 1992; Araki et al., 1990; 
Aisenman and deVellis, 1987; Drago et al., 1991; Geier et 
al., 1992; Kyprianou et al., 1991; Williams et al., 1990; 
Rodriguez-Tarduchy et al., 1990). Similarly, cells can be de- 
pendent on contact with extracellular matrix components for 
their survival (Meredith et al., 1993; Ruoslahti and Reed, 
1994; Frisch and Francis, 1994). 
In the present study, we report he existence of two path- 
ways that lead to activation of PCD in MECs: one that is acti- 
vated by DNA damage and requires the function of wt p53, 
and another that is induced by cell density and withdrawal 
of serum and that is independent of wt p53 activity. 
Starvation-induced apoptosis can be prevented by addition of 
insulin or EGF, indicating that hese polypeptides are mam- 
mary cell survival factors. These observations could be used 
to construct models of regulation of PCD in MECs, charac- 
terize PCD signal transduction pathways, and address the is- 
sue of regulation of PCD in the mammary gland in vivo. 
Materials and Methods 
Cell Lines, Tissue Culture, and Transfection 
The human breast epithelial cell lines MCF10-A (Soule et al., 1990) and 
MTSVI.7 (Bartek et al., 1991), as well as the rodent MEC lines HCll (Ball 
et al., 1988) and Nulli B (courtesy of Dr. D. Medina, Baylor College of 
Medicine, Houston, TX), were used in this study. With the exception of the 
MTSV1.7 cells that were immortalized by expression of SV40-T antigen 
(Bartek et al., 1991), all these cell lines are spontaneously immortalized 
MEC lines derived from primary culture of mammary gland explants. To 
different extents, all these cells have retained some characteristics of normal 
MECs, and they are not transformed. The MCFI0-A erbB-2 cells were de- 
rived from the MCF10-A cells by the introduction ofan expression vector 
containing the human c-erbB-2 protooncogene (Ciardieilo et al., 1992). 
The MCFI0-A and MCFI0-A erbB-2 cells were maintained in 1:1 
DME/Ham's FI2 growth medium (GM), supplemented with 10% fetal 
horse serum, EGF (10 ng/ral), insulin (5/tg/ml), hydrocortisone (10 -6 M), 
cholera enterotoxin (100 ng/ml), glutamine, and gentamycin, as described 
(Soule et al., 1990). The MTSV1.7 cells were maintained in DME sup- 
plemented with 10% FBS, insulin (10/tg/ml), hydrocortisone (5/~g/ml), 
glutamine, and gentamycin, as described (Bartek et al., 1991). The HCI1 
and Nulli B cells were maintained inRPMI 1640 GM supplemented with 
8 % FBS, EGF (10 ng/ml), insulin (5/tg/mi), glutamine and gentamycin, 
as described (Bali et al., 1988). The HL60 cells were maintained inRPMI 
1640 medium supplemented with 10% FBS, glutamine, and gentamycin, 
and used as a positive control for apoptosis (Kaufmann, 1989). Serum-free 
medium (SFM) was prepared from DME/FI2 (for MCFI0-A and MTSVl.7 
cells) or RPMI medium (for HCll and Nulli B cells) by the addition of fe- 
tuin (0.5 mg/ml), transferrin (10/~g/ml), glntamine, and gentamycin. 
The HCll cells were cotransfected with the temperature-sensitive (ts)
p53 expression vector LTRp53cGVal-135 (Michalovitz et al., 1990) and the 
pBabe-puro reporter plasmid, by the calcium phosphate precipitation 
method, as described inCben and Okayama (1987) and Merio et al. (1994). 
Transfected pools of cells were selected and maintained inRPMI medium 
containing 1 /zg/ml of puromycin (Sigma Immunochemicals, St. Louis, 
MO). Integration ofthe ts-p53 vector was confirmed by Southern blot anal- 
ysis, using a 32P-labeled mouse p53 eDNA as a probe to hybridize on 
BamHI-digested DNAs, as described in Merlo et al. (1994). 
Determination ofOptimal Drug Concentration 
The optimal concentrations of mitomycin C, cisplatin, 5-Fl-uracil, adria- 
mycin, and vincristine were determined experimentally by measuring the 
total number of dead cells after treatment with increasing concentrations 
of the drugs. The Nile blue exclusion technique was used, as described (Jeffs 
and Osmond, 1992). Equal number of cells were plated on chamber slides 
(LabTek; Nunc Inc., Naperville, IL), incubated 24 h at 37 °, and then treated 
with mitomycin C (Sigma) (1, 10, and 80 #g/nil), cisplatin (Platinol; Bristol- 
Myers Ontology Division, Evansville, IN) (1, 5, and 20 ~tg/ml), 5-Fl-uracil 
(Roche Laboratories, Nutley, N J) (1, 10, and 50/~g/ml), adriamycin (Adri- 
blastine; Farmitalia, Milan, Italy) (I, 10, and 50/tg/rni), and vincristine (On- 
covin; Eli Lilly and Co., Indianapolis, IN) (1, 10, and 80 ~tg/ml) for 3, 6, 
or 12 h at 37 °. Cells were then washed with P & C saline solution, stained 
with 1 mg/mi of Nile blue sulphate (Sigma) in P & C solution for 30 rain 
at room temperature, washed twice in P & C solution for 1 h, and scored 
by microscopy. For all cell lines, after a 12-h treatment with the maximal 
drug concentration, <I0 % of the cells could be stained with Nile blue, indi- 
cating a level of cell viability >90% under these conditions. FOr detection 
of p53 protein by immunohistochemistry, hefollowing concentrations were 
used: mitomycin C, 20/zg/ml; cisplatin, 5 ~g/ml; 5-Fl-uracil, I0 #g/ml; 
adriamycin, I0/~g/ml; and vineristine, I0/tg/ml. FOr the induction of apop- 
tosis, the following concentrations were used: mitomycin C, 40/zg/ml; 
cisplatin, I0/~g/ml; 5-Fl-uracil, 20 /~g/mi; adriamycin, 20/zg/ml; vin- 
cristine, 20/~g/ml. Using these concentrations, >95 % of the MCFI0-A and 
MTSVI.7 cells and >98% of HCII and Nulli B cells remained viable. 
p53 Immunohistochemistry 
Immunohistochemical detection of p53 protein was performed on cells 
plated on chamber slides (LabTek) and treated for 6 or 12 h with the DNA- 
damaging agents at the concentrations indicated above. The cells were 
washed with PBS three times, fixed with acetone/methanol 1:1 at -20°C 
for 10 min, washed three times with PBS, and stained for p53 using the p53- 
specific antibodies Ab2 (1801), Ab3 (240), and Ab6 (Do-1) (Oncogene 
Science Inc., Manhasset, NY). The Ab2 and Ab6 antibodies recognize an 
epitope common to wt and (most) mutant p53 proteins. The Ab3 (240) anti- 
body recognizes an epitope common to (most) mutant but not to the wt p53 
protein. For the routine cell lines HCll and Nulli B, the rabbit polyclonal 
antibody CM-I (Novocastra Laboratories, Newcastle, UK) was used. The 
slides were incubated 16 h with the antibody, at the dilution recommended 
by the manufi~urer, then a biotinylated anti-monse oranti-rabbit secondary 
antibody (Vector Laboratories, Burlingame, CA) was applied and detected 
with the conventional vidin-biotin complex method, using diaminobenzi- 
dine as chromogen. The positive nuclei were scored by microscopy, and the 
results were expressed as percentage of positive nuclei over total number 
of nuclei counted. Untreated MCFI0-A cells were also stained as negative 
controls. 
Cell Treatment and Detection of Apoptotic Nuclei 
Control experiments were initially carried out on the HL60 cells. These 
cells are known to respond to mitomycin C and undergo apoptosis with typi- 
cal DNA laddering (Kaufmann, 1989). HL60 cells were treated with 
mitomycin C (10/~g/ml) for 30 min, fixed and stained with propidium iodide 
(PI) as described below, and examined by fluorescent miscmscopy. Nuclei 
with features characteristic of apoptosis were readily observed. These 
nuclei typically appeared shrunk, condensed, fragmented, and often "ex- 
ploded" to generate characteristic apoptotic figures (Kerr et al., 1972; Wyl- 
lie, 1980, 1984). Apoptotic bodies were also observed. 
The mammary cells were plated on polystyrene chamber slides (LabTek) 
1 or 2 d before the treatment and incubated at 37°C. The medium was then 
replaced with freshly prepared rug-containing medium (mitomycin C, 40 
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tzg/ml; cisplatin, 10 ug/ml; 5-Fl-uracil, 20 ~g/ml, adriamycin, 20 ~g/mi; 
and vincristine, 20/~g/ml), and the incubation was continued for 3 h at 
37°C. The cells were then fixed with cold 2% formaldehyde in PBS, for 10 
rain at 4°C, washed once with cold PBS, and the nuclei were stained with 
a solution containing 50/zg/ml PI, 0.1% Triton X-100, 0.1% Na citrate, and 
20 #g/ml ofRNase A in PBS for 15-20 rain at room temperature. Apoptotic 
nuclei were counted within 2 h by examination of their morphology by a 
fluorescent microscopy using a Zeiss Axiophot microscope equipped with 
Neottnar 40x objective lens. The results were expressed as percentage of
the number of apoptotic nuclei (NAN) over the total number of nuclei ex- 
amined. A minimun of 1,000 nuclei were counted in each case. 
Induction of Apoptosis by Density and SFM 
Cells were trypsinized and plated on polystyrene chamber slides (LabTek) 
in the GM described above. When the cultures reached confluency, the 
medium was removed, cells were washed once with PBS and either SFM, 
SFM + EGF (10 ng/ml), SFM + insulin (5 t~g/ml), SFM + EGF + insu- 
lin, or GM was added. The cells were then incubated for additional 48 h, 
fixed, stained with PI, and scored as described above. 
Extracellular matrixq:oated chamber slides were prepared using HCII 
cells. The cells were grown to confluency in GM, then maimained in GM 
or switched to SFM for 48 h, and detached with 50 mM EDTA in PSB, es- 
sentially as described (Chammas et al., 1994). 
Analysis of the DNA Fragmentation 
Control experiments for the analysis of DNA fragmentation were initially 
carried out on the HL60 cells. 1 million HL60 cells were treated with 
mitomycin C for 30 rain, collected by centrifugation at4°C, washed with 
cold PBS, and used for DNA extraction, as described below. Upon treat- 
ment with mitomycin C, the characteristic 180-bp nucleosomal DNA lad- 
dering was readily observed. 
HCll cells were plated in 60-mm dishes (Costar Corp., Cambridge, 
MA), incubated in GM at 37°C, and then switched to SFM or to SFM + 
EGF for 48 h as described above. At the end of the incubation time, the 
cells were scraped from the dishes, combined with the supernatant, and col- 
lected by centfifugation at 4°C. The pellets were washed once with PBS and 
then either frozen at -70°C or immediately used for DNA extraction. 
DNA was extracted as follows: 200/zl of lysis buffer containing 10 mM 
Tris-HC1, pH 7.8, 10 mM EDTA, 5 mM EGTA, 0.5 % SDS, 0.1% B-mereap- 
toethanol, 50/~g/ml Pmteinase K, and 50/~g/mi RNaseA were added and 
the solution was incubated at 37°C for 2 h. The DNA was purified by phe- 
nol/chloroform extraction, ethanol precipitated, washed, dried, dissolved 
in 20/~l of TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA), and loaded 
on 1.6% agarose gels. After electrophoresis, the DNA fragments were 
visualized by ethidium bromide staining, and the gels were photographed. 
Results 
p53 Status in Mammary Epithelial Cell Lines 
The MCF10-A human breast cells express wt p53, as demon- 
strated by sequence analysis of the p53 eDNA and by single- 
strand conformation polymorphism analysis of the p53 gene 
(Diella et al., 1993). Staining with p53 antibodies i  also 
consistent with the presence of wt p53 (see below). The 
MTSV1.7 human breast cells were established from primary 
cultures by the introduction of a vector expressing SV-40 T 
large antigen (Bartek et al., 1991), which is known to bind 
to and inactivate ndogenous wt p53 (Ludlow, 1993). The 
murine Hel l  cells contain two allelic mutations intheir p53 
gene and no wt p53 (Merle et al., 1994). Accordingly, over- 
expression of p53 protein is detected with the CM-1 p53 an- 
tlserum (data not shown). The Nulli B cells were obtained 
from nmnmmry gland explants of mice with a homozygous 
p53 gene knock-out (Donehower t al., 1992) and, therefore, 
are devoid of any endogenous p53 protein. Accordingly, no 
p53 protein was detected by immunohistochemistry (data 
not shown). 
p53 is Required for DNA Damage-induced PCD in 
Hell Cells 
Wild-type p53 is thought to have a role in detecting DNA 
damage and in activating PCD. We have tested MECs with 
different p53 status for drug-induced PCD. Treatment of the 
Hel l  cells plated at various densities with mitomycin C, 
cisplatin, 5-Fl-uracil, adriamycin, and vincristine at sub- 
lethal doses did not induce any increase in the NAN (data 
not shown). Thus, the absence of functional wt p53 in HCll 
cells correlates with their inability to respond to DNA- 
damaging agents in the activation of PCD. 
The HCll cells were transfected with an expression vector 
containing ts p53 (Michalovitz et al., 1990; Merle et al., 
1994). The ts p53 vector expresses a p53 protein that re- 
mains mostly in the mutant conformation at 37°C and is 
mostly in the wt conformation at32.5°C. After transfection 
and selection, DNA was extracted from pools of resistant 
cells and tested for the presence ofts p53 vector by Southern 
blot analysis. The expected hybridization fragments corre- 
sponding to ts p53 were observed in the transfected cells 
(Fig. 1 B). The endogenous p53 gene and pseudogene were 
also observed (Fig. 1 B). 
The ts p53 Hel l  cells were then maintained at 37°C or 
at 32°C for 48 h and tested for apoptosis. Parental Hel l  
cells were also maintained at 37°C and 32°e for compari- 
son. While parental HC11 cells showed no difference in the 
NAN at 32°C or at 37°C, a 2.5-fold increase in the NAN was 
observed between ts p53-transfected HC11 cells maintained 
at 32°C vs 37°C (Fig. 1 C). These data indicate that wt p53 
can by itself be a weak activator of PCD in these cells. 
Paremal and ts p53-transfected HCll cells were then 
maintained at 37°C or at 32°C, and were tested for DNA 
damage-induced apoptosis using mitomycin C, cisplatin, 
5-Fl-uracil, and adriamycin. At the same time, the cells were 
also tested with the non-DNA damaging agent vincristine. 
The parental Hel l  cells maintained at 37°C or 32°C re- 
mained unresponsive tothe drug treatment (Fig. 1 C). The 
ts p53 Hel l  cells maintained at 37°C also did not respond 
to any treatment. In contrast, the ts p53-transfected cells 
maintained at32°C showed athreefold increase in NAN over 
the untreated cells after treatment with mitomycin C (Fig. 1, 
A and C). This level of activation of PCD is comparable to 
that seen with the MCF10-A cells (see below). Only a slight 
increase in the NAN was seen with cisplatin and none with 
5-Fl-uracil, adriamycin (data not shown), or vincristine. 
This result indicates that in HCll cells the activation of apop- 
tosis in response to mitomycin C-induced DNA damage re- 
quires a wt p53 function. 
The Nulli B and the human cell line MTSV1.7, which also 
lack functional wt p53, were tested with the same DNA- 
damaging agents, and as seen for the HCll cells did not show 
an increase in NAN (data not shown). 
wt p53 Accumulates in Response toDNA Damage in 
MCFIO-A Cells 
The p53 specific antibodies Ab2 (Abl801) and Ab6 (DO-l) 
were used to detect the p53 protein in MCF10-A cells by im- 
munohistochemistry. These antibodies recognize wt and 
(rues0 mutant p53 proteins. Using the Ab2 and Ab6 antibod- 
ies, untreated MCFI0-A cells showed very few p53-positive 
cells (<3%) (Fig. 2; Table I). These results are consistent 
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Figure 1. Apoptosis in HC11 cells transfected with the ts-p53 v ctor after treatment with DNA-damaging agents. (.4) Photomicrography 
of PI-stained nuclei from untreated ts-p53 HCll cells (left), compared to cells treated with (left to right) mitomycin C, eisplatin, and 
vincristine, at 32°C. At this temperature, the ts-p53 protein is mostly in wt conformation (Michalovitz et al., 1990). Nuclei with typical 
morphological features of apoptosis are indicated (white arrows). (B) Southern blot analysis of genomic DNA from parental (left lane) 
and ts-p53-transfected HC11 cells (right lane) hybridized with labeled mouse p53 eDNA. The endogenous p53 gene and pseudogene 
can be observed in both DNA samples (thin arrows on the left). The 14- and a 2.2-kb hybridizing fragments diagnostic of the ts-p53 
vector (thick arrows on the right) are visible in the transfected ceils. (C) NAN after treatement ofparental and ts-p53 HC 11 ceils with 
mitomycin C (hatched bars), cisplatin (gridded bars), or vincristine (open bars) at 37°C (left half) or at 32°C (right half), compared 
to the untreated cells (solid bars). The NAN is expressed in percentages as the number of apoptotic nuclei over the total number of nuclei 
counted. Standard deviation is in all cases within + 10%. 
with the presence of wt p53 in these cells. This low level of 
p53 positivity is probably caused by posttranslational stabili- 
zation of p53 protein that does not reflect he presence of a 
mutation, as described for other c ll systems (Delmolino et 
al., 1993; Lehman et al., 1993; Vojtesek and Lane, 1993). 
Using the Ab3 (Ab240) antibody, which recognizes (most) 
mutant forms of p53 but not the wt p53, MCF10-A cells 
showed no staining, as expected (data not shown). 
After treatment of the MCF10-A cells with the DNA- 
damaging agents mitomycin C, 5-Fl-uracil, and adriamycin, 
respectively, a DNA alkylating agent, a nucleoside analogue, 
and a topoisomerase H-dependent intercalating agent (Cala- 
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Figure 2. p53 immunoreactivity of 
MCF10-A ceils treated with DNA- 
damaging agents. Results with the Ab2 
anti-p53 antibody are shown. Treat- 
ments are for 6 h. Untreated ceils (top 
left) and cells treated with vincristine 
(top right), a non-DNA-damaging 
drug, showed few p53 immunoreactive 
nuclei. Ceils treated with mitomycin C 
and 5-Fl-uracil (bottom, left and right) 
showed intense p53 immunostaining. 
bresi and Chabner, 1993), the number ofp53-positive nuclei 
markedly increased (Fig 2; Table I). Using either antibodies 
Ab2 or Ab6, 80-90% of the nuclei were strongly positive for
p53 after 12 h of treatment, a 26-30-fold increase over the 
untreated cells. After 6 h of treatment, a 24-, a 14-, and a 
27-fold increase in the number of positive nuclei was ob- 
served, respectively, with mitomycin C, 5-Fl-uracil, and 
adriamycin. Cisplatin, an intercalating agent that causes 
breaks in the DNA (Calabresi and Chabner, 1993), was less 
efficient, and induced only a sevenfold increase in the num- 
ber of p53-positive nuclei over untreated cells after 6 h of 
treatment (Table I). Technical reasons prevented long-term 
treatment of MCFI0-A cells with cisplatin. 
Treatment with the non-DNA damaging agents vincristine 
and methotrexate, r spectively, an inhibitor of microtubules 
function and an inhibitor of purine biosynthesis (Calabresi 
and Chabner, 1993), for 6 or 12 h resulted in only a slight 
increase in the number of p53-positive nuclei (three- and 
eightfold higher than untreated cells after 6 and 12 h of treat- 
ment, respectively, Fig. 2; Table I). Thus, chemically in- 
duced DNA damage fficiently leads to the accumulation of
immunoreactive p53 in the nucleus of MCFI0-A cells. 
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Table I. Expression of p53 in MCFIO-A Cells after 
Treatment with DNA-damaging A ents 
p53 expression* 
Treatment time 
Drug 6 h 12 h 
Untreated <3 % <3 % 
Mitomycin 71% 93 % 
Cisplatin 21% ND* 
5-Fl-uracil 42 % 83 % 
Adriamycin 82 % 75 % 
Methotrexate 9 % 25 % 
Vincristine 8 % 25 % 
* The data shown here were obtained with the Ab2 antibody. The results with 
the Ab6 antibody were essentially indentical. Staining with the Ab3 antibody 
gave negative results in all cases. 
at AtI cells detached from the slide after 12 h treatment with cisplatin, p53 ex- 
pression could not be determined. 
DNA-damaging A ents Induce Apoptosis 
in MCFIO-A Cells 
Subconfluent cultures of MCF10-A cells were treated with 
mitomycin C (40/~g/ml), cisplatin (10 #g/ml), 5-Fl-uracil 
(20 t~g/ml), adriamycin (20 /~g/ml), and vincristine (10 
/~g/ml) for 3 h, and the NAN were recorded by PI staining 
and microscopic examination. Mitomycin C induced a four- 
fold increase in the NAN over untreated cells (Fig. 3). The 
effect of mitomycin C on MCF10-A cells was dose dependent 
in the concentration range 20-100 #g/ml (data not shown). 
The experiment was repeated on cultures of MCF10-A cells 
at high density with similar results (data not shown). Under 
the same conditions, cisplatin, 5-Fl-uracil, and adriamycin 
did not elicit an apoptotic response. This result was surpris- 
ing since 5-Fl-uracil and adriamycin could efficiently induce 
accumulation fp53 in the MCF10-A nuclei. To rule out the 
possibility that this result was caused by a nonoptimal treat- 
ment regimen, the experiment was repeated with increasing 
drug concentration (20-120 ttg/ml) and for longer time (3-12 
h). None of these treatments led to an increase in the basal 
level of apoptosis een in the untreated cells. At higher 
doses, instead, the drugs caused 100% necrotic ell death. 
MCFIO-A Cells Overexpressing c-erbB-2 Respond 
Differently to DNA Damage 
Human breast cancer cells may differ in their apoptotic re- 
sponse to DNA-damaging agents from the normal epithelial 
cells. Since most cancer cell lines available contain muta- 
tions in their p53 gene, we chose to analyze in vitro-trans- 
formed MCF10-A cells, which express wt p53, for activa- 
tion of PCD upon chemically induced DNA damage. The 
MCFI0-A ErbB-2 cells were derived from the MCF10-A 
cells by the overexpression f the c-erbB-2 proto-oncogene, 
and they have acquired the ability to form colonies in soft 
agar (Ciardiello et al., 1992; Bianco et al., 1994). 
The MCF10-A ErbB-2 cells were treated with mitomycin 
C, cisplatin, 5-Fl-uracil, adriamycin, and vincristine in the 
same conditions as for the MCF10-A cells, and the NAN was 
scored. Mitomicin C could elicit an apoptotic response com- 
parable (sixfold over the untreated cells) to that seen with the 
MCF10-A cells (Figs. 3 B and 4). In addition, cisplatin and 
5-Fl-uracil treatment ofthese cells led to, respectively, a 6.5- 
and a 3-fold increase in the NAN (Fig. 4), an effect not seen 
with the MCF10-A cells (Fig. 3 B). These data indicate that 
there might be a synergy between ErbB-2 signaling and 
DNA damage-induced p53 activation in PCD. 
Induction of Apoptosis by Confluency and SFM 
Cultures of MCF10-A, Nulli B, HC11 and MTSV1.7 MEC 
were maintained in GM, which contains FBS, EGF and in- 
sulin, allowed to grow to different levels of confluency, and 
switched to SFM. After 48 h in SFM; the cells were stained 
with PI and scored for the NAN. Little or no difference was 
observed in the NAN in subconfluent MCFI0-A, Nulli B, 
and HC11 cells when these cells were switched to SFM (Fig. 
5). With the exception of the MTSV1.7 cells, MECs grown 
to confluency in GM did not significantly undergo apoptosis 
over basal evels. In contrast, aremarkable increase in NAN 
was observed with all the MEC lines tested when the ceils 
were allowed to reach confluency and then switched to SFM 
for 48 h (Fig. 5). The confluent MCF10-A, HC11, Nulli B, 
and MTSV1.7 cells in SFM showed a 8-, 7.5-, 8- and 3-fold 
increase in NAN, respectively, compared to confluent cells 
in GM. Since these various cell lines have a different p53 sta- 
tus, we conclude that SFM and confluency-induced apopto- 
sis occurs independently of the function of wt p53. 
We have previously shown that HCll cells deposit ECM 
proteins, which contribute to their ability to differentiate 
(Chammas et al., 1994). Therefore, we examined whether 
cell-matrix interactions at confluency could induce the 
apoptotic signal. HCll cells were grown to confluency and 
maintained either in GM or in SFM for 48 h. The cells were 
then removed from the culture dishes using a protocol that 
preserves the biological activity of extracellular matrix com- 
ponents (Chammas et al., 1994). Low numbers of HCll, 
MCF10-A, MTSVI.7, and Nulli B ceils were then plated on 
the extracellular matrix-coated dishes and maintained either 
in GM or in SFM for 48 h. In no case did the exogenous ex- 
tracellular matrix activate PCD in any of the sparse MEC 
lines (data not shown). This result makes it unlikely that 
changes in extracellular matrix composition or assembly in 
confluent cultures induce apoptosis. 
EGF and Insulin Are Survival Factors 
We then tested the ability of EGF and insulin to restore sur- 
vival of MECs. As illustrated in Fig. 6, both EGF (10 ng/ml) 
and insulin (5 #g/ml) efficiently blocked starvation-induced 
PCD of the MCFI0-A, the HCll, and the Nulli B cells, 
reducing the NAN to levels comparable to those observed 
when cells are maintained in GM. For these cell lines EGF 
seemed to be more potent han insulin. The MTSV1.7 cells 
were only partially protected by EGE In all cases, the addi- 
tion of EGF and insulin together completely protected the 
cells from apoptosis. Finally, DNA fragmentation a alysis 
was carried out on DNA extracted from HCll cells main- 
tained in GM, SFM, or SFM supplemented with EGF (10 
ng/ml). A characteristic ladder of nucleosomal-sized DNA 
fragments was visible in the DNA from cells maintained in
SFM, while no such DNA ladder was observed when cells 
were maintained inGM or in EGF-supplemented SFM (Fig. 
7). This resuk confirms the apoptotic nature of the effects de- 
scribed above. 
No DNA laddering could be observed in the DNA ex- 
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Figure 3. Detection of apoptosis n MCF10-A ceils after treatment with DNA damaging agents. (A) PI staining of nuclei from untreated 
MCF10-A cells (left) compared to nuclei from ceils treated with mitomycin C (center) and vincristine (right). An example of a nucleus 
with characteristic features of apoptosis indicated (white arrow). (B) NAN in cultures of untreated MCF10-A ceils (open bar) or cells 
treated with DNA-damaging agents. Legend to the drug treatments i shown in the panel. Treatment with mitomycin C induced afourfold 
increase in NAN. The NAN is expressed in percentages as the number of apoptotic nuclei over the number of nuclei counted, o, un- 
treated; ~, mitomycin; [], cisplatin; [],5-Fl-uracil; [], adriamycin; -, vincristine. 
tracted from confluent Nulli B or MTSV1.7 cells maintained 
in SFM (data not shown). The reason for this is unknown, 
but it reinforces the idea that apoptosis can occur in the ab- 
sence of detectable DNA laddering (Collins et al., 1992). 
Discussion 
The results presented indicate that two distinct pathways 
which differ in their requirement for wt p53 can lead to the 
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MCF10-A erbB-2  
Figure 4. Detection of apoptosis n MCF10-A ErbB-2 cells after 
treatment with DNA-damaging agents. Legend to the drug treat- 
ments is the same as in Fig. 3 and is indicated in the panel. Treat- 
ment with mitomycin C, cisplatin, and 5-Fl-uracile induced, 
respectively, a 6-, 6.5-, and 3-fold increase in NAN. The NAN is 
expressed in percentages as the number of apoptotic nuclei over the 
number of nuclei counted. Symbols have the same representations 
as in Fig. 3. 
activation of PCD in nontransformed MECs. Thus, wt p53 
is not required for all signaling pathways leading to apop- 
tosis. 
A role for wt p53 in detecting DNA damage is being in- 
creasingly recognized (Lane, 1992). Upon UV irradiation 
(Hall et al., 1993), -r-irradiation (Kastan et al., 1991; Kuer- 
bitz et al., 1992; Lowe et al., 1993b), or treatment with 
DNA-damaging anticancer chemotherapy drugs (Fritsche t 
al., 1993; Lowe et al., 1993a), cellular p53 was shown to 
rapidly accumulate in the nucleus and to induce a cell cycle 
arrest. This would then allow for DNA repair to occur. Our 
results on MECs confirm this notion, since treatment of the 
MCF10-A cells with the DNA-damaging agents mitomycin 
C, 5-Fl-uracil, adriamycin, and to a lower extent, cisplatin, 
led to rapid nuclear accumulation ofthe p53 protein. At the 
same time, excessive DNA damage is known to commit he 
cell to PCD in awt  p53-dependent manner (Lane, 1992; 
Clarke et al., 1993; Lowe et al., 1993a). The results we have 
obtained on our panel of MEC lines confirm in part this 
function of wt p53, in that mitomycin C treatment led to 
a p53-dependent increase in apoptosis. It is intriguing, 
though, that treatment with 5-Fl-uracil and adriamycin did 
not elicit apoptosis in the MCF10-A cells, in spite of the 
rapid accumulation fwt p53 in the treated cells. High doses 
of 5-Fl-uracil and adriamycin caused necrotic cell death. 
Since these drugs induce DNA damage by different mecha- 
nisms (Calabresi and Chabner, 1992), the failure of these 
drugs to induce apoptosis may be caused by differences in
the type and amount of DNA damage. 
Interestingly, the MCF10-A cells transformed by high ex- 
pression levels of ErbB-2 behaved ifferently from the paren- 
tal MCF10-A cells. These cells responded to mitomycin C, 
cisplatin, and to a lesser extent, 5-Fl-uracil treatment with 
increased PCD. Thus, the PCD-stimulating activity of DNA- 
damaging drugs does not only depend on wt p53, but can be 
modulated by activating the ErbB-2 receptor tyrosine kinase. 
In fact, ErbB-2-specific agonistic antibodies have been 
shown to increase the cytotoxicity of cisplatin treatment on 
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Figure 5. Apoptosis induced by cell density and SFM. Results with 
MCF10-A, HCll, MTSV1.7, and Nulli B cells are shown. Cells 
were plated in GM, allowed to reach different densities ( parse or 
confluent), then either switched to SFM (hatched bars) or main- 
mined in GM (open bars) for an additional 48 h. The results ob- 
tained with sparse or confluent cultures are shown. The NAN is 
expressed in percentages as the number of apoptotic nuclei over the 
number of nuclei counted. 
human breast carcinoma cells. Receptor signaling appears to 
be required for this effect (Arteaga et al., 1994). This obser- 
vation is of great interest in oncology since c-erbB-2 is am- 
plified and/or overexpressed in a significant subset of human 
breast cancers. Tumors that harbor c-erbB-2 amplification 
may have a defined sensitivity to chemotherapy involving the 
use of DNA-damaging drugs. If this is true, the regulation 
of PCD in cancer cells will become an area of intense re- 
search in oncology. 
The requirement for wt p53 function in DNA damage- 
induced PCD in MECs was demonstrated bythe lack of re- 
sponse in cells with altered p53 and the subsequent experi- 
ments in which introduction ofwt p53 in HC11 cells restored 
their responsiveness to mitomycin C. These observations 
support a central role of wt p53 in activating PCD in re- 
sponse to DNA damage, although it is not a universal feature 
of mammalian cells. In fact, HL60 cells lack endogenous 
p53 (Kastan et al., 1991), and yet they rapidly undergo apop- 
tosis after DNA damage (Kaufmann, 1989). 
It has previously been reported that in myeloid and leuke- 
mia cell lines the introduction of wt p53 could induce high 
levels of apoptosis and a significant loss of cell viability 
(Shaw et al., 1992; Yonish-Rouach et al., 1991; Ryan et al., 
1993). The expression ofwt p53 in HC11 cells by itself could 
induce low levels of apoptosis, although the effect was more 
limited. This observation could reflect differences in cell 
type or could be explained by differences in the extent of 
DNA damage that the cells have accumulated in the absence 
of wt p53. The activity of exogenous p53 protein indeed e- 
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Figure 6. EGF and insulin as 
survival factors for mammary 
epithelial cells. The results 
obtained with the MCF10-A, 
HCll, MTSV1.7, and Nulli 
B cell lines are shown. Cells 
were plated and maintained in 
GM (solid bars) or switched 
to SFM (hatched bars), SFM 
+ EGF (open bars), SFM + 
insulin (horizontal bars), 
or SFM + EGF + insulin 
(gridded bars) for 48 h. Both 
EGF and insulin at the con- 
centration used (10 ng/ml and 
5 #g/ml, respectively) showed 
a survival factor activity. The 
NAN is expressed in percent- 
ages as the number of apop- 
totic nuclei over the number 
of nuclei counted. 
pends on the "cellular environment" in which it is expressed 
(Vojtesek and Lane, 1993). 
The second pathway that activates PCD involves the com- 
bined effect of high cell density and SFM, and it is clearly 
independent of the wt p53 function. The existence of p53- 
independent pathways has also been shown in thymocytes 
(Clarke et al., 1993). In contrast, IL-3-dependent hemato- 
poietic cells require p53 for both DNA damage- and starva- 
tion-induced apoptosis (Gottlieb et al., 1994). Starvation- 
induced PCD likely reflects the depletion of a cell-type 
specific survival factor(s). Examples of survival factors in- 
clude PDGF for glial cells (Barres et al., 1992), FGF for en- 
dothelial cells (Araki et al., 1990) and for fibroblasts (Tamm 
et al., 1991), insulin-like growth factors (IFGs) for neuronal 
cells (Aisenman and deVellis, 1987; Drago et al., 1991; 
Banes et al., 1992) and breast cancer cells (Geier et al., 
1992), estrogens for MCF-7 breast cancer cells (Kyprianou 
et al., 1991), and IL-3 for myeloid cells (Williams et al., 
1990; Rodriguez-Tarduchy et al., 1990). The hypothesis that 
the GM contains MEC-specific survival factors was fully 
confirmed by subsequent experiments in which EGF and in- 
sulin were added to the SFM and shown to have this prop- 
erty. These properties are not unique to a particular cell line, 
but they appear to be a general property of MECs. 
An interesting aspect of starvation-induced apoptosis is 
the fact that serum, insulin, and EGF deprivation are not 
sufficient by themselves toefficiently induce apoptosis. Sub- 
confluent cultures of cells maintained in SFM responded 
very little or not at all, whereas tarvation of the confluent 
cultures led to a large increase in PCD. Identical results, 
i.e., little or no activation of PCD, were obtained with sub- 
confluent cultures of cells plated on an extracellular matrix 
deposited by HCll cells induced to undergo PCD. These 
results argue for a primary role of cell-cell contact in the ini- 
tial signaling for apoptosis. What the signal might be is cur- 
Figure 7. DNA fragmentation in the HC11 cells. Agarose gel elec- 
trophoresis of DNA from HCll cells maintained in (left to right) 
GM, SFM, or SFM + EGF (10 ng/ml) for 48 h. A laddering of 
DNA fragments 180 bp or multiple in size, characteristic of apopto- 
sis, was detected in the DNA from cells in SFM (left arrows), but 
not in the DNA from cells in GM. Addition of EGF to the SFM 
completely prevented this DNA fragmentation. Molecular weight 
marker (123-bp ladder) is shown n the right. 
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rently unknown, but cadherin-type molecules may be in- 
volved, and it is possible that cell density leads to changes 
in the status and function of surface receptors, as well as in- 
creased sensitivity to EGF and insulin depletion. A differ- 
ent role of cell-matrix interaction can be envisioned. In 
confluent cultures of mammary cells, integrin-like surface 
receptors may progressively lose the ability to contact their 
ligand, or the accessibility of extracellular matrix compo- 
nents might change (Ruoslahti and Reed, 1994). Cell contact 
signals might cause or accompany changes in the deposition 
or interaction with extracellular matrix components, which 
in turn sensitize the cells to EGF and insulin depletion. In 
kidney cells, for example, density and cell contact is neces- 
sary for efficient induction of apoptosis by disruption of 
cell-matrix interaction (Frisch and Francis, 1994). This and 
other eports upport the idea that proper cell-matrix inter- 
action can indeed be regarded as a survival factor (Meredith 
et al., 1993). The importance of cell-cell and cell-matrix 
contact in PCD of MEC will be addressed in the future. 
During postlaetational involution of the mammary gland, 
a large fraction of epithelial cells are eliminated by PCD 
(Walker et al., 1989; Strange t al., 1992), and this is accom- 
panied by extensive tissue remodeling (Strange t al., 1992). 
Comparing the data presented here, obtained from cultured 
MECs with the physiological ctivation of PCD that occurs 
in vivo, the following similarity can be noticed: in vitro, se- 
rum depletion combined with cell density creates acondition 
of dependency on EGF or insulin for cell survival. In vivo, 
at the time of initiation of involution, the epithelial cells in 
the mammary gland are in tight contact with each other and 
almost completely occupy the parenchymal space (Walker et 
al., 1989; Strange t al., 1992). Whether adrop in the local 
levels of EGF (or other members of the EGF family of 
growth factors) and insulin (or IGFs) occurs and plays a role 
in the involution of the mammary gland remains to be estab- 
lished. Little is known about he sequence of signals that lead 
to PCD during mammary gland involution. However, intra- 
cellular signal transducers including PKA and AP-1 (fos/ 
junD) have been recently shown to be activated uring invo- 
lution (Marti et al., 1994). The results described here may 
provide a model system for PCD in MEC to help in the 
description of the molecular events involved in the breast in- 
volution process. 
The data presented on SFM-induced activation of PCD 
clearly indicate that this effect is independent of wt p53 in 
vitro. It would be interesting to confirm this relationship n
vivo, using homozygous p53 knock-out mice (Donehower t 
al., 1992) and examining whether their mammary glands are 
able to undergo normal differentiation a d involution. 
Compared to their normal counterparts, cancer cells may 
acquire neoplastic properties by losing their ability to re- 
spond to the apoptotic signals and consequently acquire 
novel survival capacity. Thus tumorigenesis may reflect he 
combined effect of growth promoting and antiapoptotic mol- 
ecules (Miknlski, 1994). The neoplastic phenotype ofbreast 
cancer cells may be caused in part by the autocrine xpres- 
sion of antiapoptotic factors that prevent he tumor cells 
from entering PCD and provide indefinite survival capacity. 
The identification of insulin and EGF as MEC survival fac- 
tors raises the possibility that EGF-like and insulin-like 
growth factors also play a role in human breast umorigene- 
sis. It has been shown that IGFs can prevent or delay apopto- 
sis in several cell types (Barres et al., 1992; Aisenman and 
deVellis, 1987; Drago et al., 1991), including breast cancer 
cells (Geier et al., 1992). It has also been shown that IGF-II 
cooperates with SV-40 T large antigen during tumor progres- 
sion by providing for an antiapoptotic signal rather than 
a mitogenic signal (Christofori et al., 1994). Breast can- 
cer cells are known to express IGF-1 receptors on their sur- 
face (CuUen et al., 1990; Pekonen et al., 1988; Foekens 
et al., 1989), and high IGF I and II levels are found in breast 
cancer specimens, acting in a paracrine fashion (Yee et al., 
1988, 1989; Cullen et al., 1991; Osborne et al., 1989). 
Similarly, ras-transformed MECs synthesize and secrete ac- 
tive TGF-c~ (Ciardiello et al., 1988), a peptide growth fac- 
tor related to EGF, and human breast carcinomas express at 
least hree EGF-related polypeptides, TGF-a, amphiregulin, 
and cripto-1 (Ciardiello et al., 1989; Qi et al., 1994), provid- 
ing strong support for a role of EGF and EGF-related growth 
factors in breast carcinogenesis. Our data are consistent with 
the attractive possibility that breast cancer cells use IGFs and 
TGF-ct to create an autocrine activation of antiapoptotic 
pathways. Whether oncogene-mediated in vitro transforma- 
tion of the HC11 cells can modify their requirement for EGF 
or insulin for survival remains an open question and will be 
addressed. 
Knowledge about the mechanisms of DNA damage- 
induced PCD also has implications in cancer management. 
In our in vitro system the alkylating agent mitomycin C can 
activate PCD in a p53-dependent manner. Loss, mutation, 
or inactivation of p53 in breast umors may be correlated 
with resistance to a given chemotherapy that involves DNA 
damage, p53 mutations are found in a high fraction of 
(~30%), but not all human breast carcinomas (Harris, 
1992; Osborne t al., 1991). There is hope that information 
about he status of p53 in a given tumor specimen might help 
predict patients' responses to a given DNA-damaging drug 
used in chemotherapy. 
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